NVO
The good news nobody wanted to buy
Novo Nordisk did what companies usually hope will calm the room: it raised guidance. But the market’s mood was more like, “Cool story, show me the growth.” Shares slid after the company reported second-quarter sales of 78.488 billion Danish kroner, up just 2% year over year, while the bigger headline was the ugly comparison to first quarter sales.
The company said the quarter faced a tough setup thanks to a DKK 2.6 billion rebate provision reversal tied to the U.S. 340B Drug Pricing Program in the prior year. Translation: last year’s comparison was artificially flattering, and this year’s numbers had to run uphill with a backpack on.
Why the stock is sulking
Novo also took 6.3 billion Danish kroner in non-cash impairment charges tied to intangible pipeline assets, including monlunabant. That kind of write-down is basically the corporate version of admitting one of your side quests did not, in fact, become the main quest.
The bright spot: GLP-1 demand still looks alive and kicking.
- Wegovy injectable sales reached 19.484 billion Danish kroner
- Wegovy pill generated 3.218 billion Danish kroner
- Ozempic sales rose 3% to 31.375 billion Danish kroner
CEO Mike Doustdar said strong U.S. GLP-1 momentum and international launches led the company to raise its 2026 outlook for adjusted sales and operating profit. Novo now expects adjusted sales and adjusted operating profit growth to decline between 0% and 6% at CER, better than the prior guide of a 4% to 12% decline.
Big picture
This is the classic “good, but not good enough” earnings reaction. Novo still owns one of the hottest corners of pharma, but when growth slows and expectations are sky-high, even a guide-up can feel like a shrug. For investors, the message is simple: the GLP-1 party isn’t over — but the easy money phase may be.